Dual Therapy With Renally Adjusted Lamivudine and Dolutegravir: A Switch Strategy to Manage Comorbidity and Toxicity in Older, Suppressed Patients?

HIV Medicine - United Kingdom
doi 10.1111/hiv.12781
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Lipid Profile Improvement in Virologically Suppressed HIV-1-infected Patients Switched to Dolutegravir/Abacavir/Lamivudine: Data From the SCOLTA Project

Infection and Drug Resistance
Infectious DiseasesPharmacology
2019English

Dolutegravir/Abacavir/Lamivudine Versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study

Antiviral Therapy
Infectious DiseasesPharmacology
2017English

Real-Life Study of Dual Therapy Based on Dolutegravir and Ritonavir-Boosted Darunavir in HIV-1-infected Treatment-Experienced Patients

PLoS ONE
Multidisciplinary
2019English

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy

PLoS ONE
Multidisciplinary
2016English

Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching From Ritonavir-Boosted Protease Inhibitors to Raltegravir

AIDS Research and Human Retroviruses
VirologyInfectious DiseasesImmunology
2013English

Patient‐Reported Comorbidity and Survival in Older Adults With Cancer

Oncologist
Cancer ResearchMedicineOncology
2017English

Cardiovascular Comorbidity in Multiple Sclerosis Patients Treated With Mitoxantrone Therapy: A Cohort Study

Multiple Sclerosis and Demyelinating Disorders
AllergyImmunologyNeurology
2017English

Reduced Toxicity Breast Cancer Therapy: Changing the or to and in Dual Targeted Therapeutics

2010English

Erratum To: Add-On Adefovir Is Superior to a Switch to Entecavir as Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B

Digestive Diseases and Sciences
PhysiologyGastroenterology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy